2 Beaten-Down GLP-1 Stocks to Buy on the Dip
Don't wait until clinical milestones send their share prices soaring.
Read the full articleYou might also wanna read
The post-Ozempic economy: Investors bet on foodtech
Interest in GLP-1s is a growing global phenomenon. See why investors in adjacent lifestyle categories are taking notice.
3 High Growth GLP-1 Biotech Winners to Buy in July
The GLP-1 trade has matured from a single-stock story into a tiered opportunity set. Demand for obesity therapeutics keeps expanding as lowe
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short in
Pharma stocks are showing strength. Charts predict this name could break out next
Pharmaceutical stocks have recently separated themselves from the broader market, and the group has become a source of leadership within hea
cnbc.com·1mo ago
Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity
The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow proc
How new weight-loss drugs may offer hope for curbing addiction
Drugmakers are racing to develop ever newer versions of the GLP-1 drugs, and regulators around the world are approving them at an equally ra
Comments
Sign in to join the conversation.
No comments yet. Be the first.